Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
暂无分享,去创建一个
R. Porcher | J. Bourhis | H. Tilly | M. Bernard | D. Blaise | E. Deconinck | L. Adès | J. Cassuto | N. Ifrah | T. Facon | G. Socié | N. Milpied | P. Bordigoni | M. Attal | R. Tabrizi | M. Kuentz | J. Vernant | F. Garban | B. Lioure | M. Michallet | S. Vigouroux | M. Renaud | P. Chevalier
[1] Wen-yu Li,et al. Evaluation of the Rituximab Maintenance Improves Clinical Outcome of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma,Both in Patients with and without Rituximab during Induction:Results of A Prospective Randomized Phase III Intergroup Trial , 2007 .
[2] W. Hiddemann,et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a pros , 2006, Blood.
[3] Max Wolf,et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.
[4] R. Kamble,et al. Rituximab responsive refractory acute graft-versus-host disease. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] G. Salles,et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2006, Blood.
[6] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[7] M. Maris,et al. Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma. , 2005 .
[8] P. Mclaughlin,et al. Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL). , 2005 .
[9] R. Gressin,et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. , 2005, Blood.
[10] J. Hainsworth,et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Craddock,et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. , 2004, Blood.
[12] N. Schmitz,et al. Reduced Intensity Allogeneic Stem Cell Transplantation for Hodgkin’s Disease. Outcome Depends Primarily on Disease Status at the Time of Transplantation. , 2004 .
[13] R. Gascoyne,et al. Long‐term disease‐free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation , 2004, British journal of haematology.
[14] V. Diehl,et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. , 2004, Blood.
[15] M. Ghielmini,et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.
[16] J. Raemaekers,et al. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation , 2003, Bone Marrow Transplantation.
[17] Ruta Bajorunaite,et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. , 2003, Blood.
[18] M. Sydes,et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] P. Mclaughlin,et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] N. Schmitz,et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. , 2002, Blood.
[21] B. Quesnel,et al. Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study , 2002, Bone Marrow Transplantation.
[22] P. Mclaughlin,et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. , 2001, Blood.
[23] P. Bierman. Allogeneic bone marrow transplantation for lymphoma. , 2000, Blood reviews.
[24] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Armitage,et al. Allogeneic bone marrow transplantation for low-grade lymphoma. , 1998, Blood.
[26] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[27] L. Verdonck,et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. , 1997, Blood.